secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-036306
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025
------------------------------------------------------------------------

- Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.
- Cash and equivalents $110.8M; expected to fund operations into Q4 2026 through multiple clinical readouts.
- PIKture-01 Part A monotherapy enrollment near complete; PK and preliminary efficacy data expected H2 2025.
- Part B fulvestrant combination dosing initiated through 900 mg BID cohort; initial data due H2 2025.
- Pan-mutant PI3Kα development candidate to be announced in Q2 2025; aims for ~10x selectivity over wild type.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017025036306/0000950170-25-036306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017025036306/okur-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer